REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1591059
This article is part of the Research TopicNational Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and TreatmentView all 5 articles
Global Research Landscape of Antiangiogenic Therapy for Colorectal Cancer: A Bibliometric Analysis of Mechanistic Insights and Clinical Advancements
Provisionally accepted
- 1Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, Shanghai Municipality, China
- 2Department of Neurology, First Affiliated Hospital of Jiaxing University, Jiaxing, China
- 3Department of Gastroenterology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Colorectal cancer (CRC) is a major global health issue, with over 1.9 million diagnoses yearly and low survival rates in advanced stages. Antiangiogenic therapies (AAT) targeting VEGF and VEGFR have improved outcomes, but resistance mechanisms limit their effectiveness. This study uses bibliometric analysis to link mechanistic insights, such as VEGF splicing variants, with clinical developments, identify global collaboration trends, and propose strategies to reduce resistance and toxicity in treatments. Methods: This study were used to search the Web of Science databases Core Collection. Studies published in English from 1996 to 2024 were included for analysis. VOSviewer 1.6.20, CiteSpace 6.4.R1, and R 4.4.1 were employed for bibliometric analysis and visualization. Results: This bibliometric analysis of 976 publications from 1996 to 2024 shows a 13.65% annual growth rate in CRC antiangiogenic research. China leads with 20.5% of publications, followed by the USA at 15.7% and Japan at 13.1%. Key institutions include Assistance Publique Hôpitaux de Paris, and notable journals are BMC Cancer and Clinical Colorectal Cancer. Keyword evolution reflects a shift from angiogenesis mechanisms to clinical validation of treatments like FOLFIRI with bevacizumab, with a current focus on tumor microenvironment reprogramming and precision survival analytics (2020-2024, burst intensity 6.66). Key milestones include Phase III trials like AVF2107g and ctDNA-guided strategies, along with emerging dual-target inhibitors. Conclusion: This bibliometric analysis reveals a shift from VEGF studies to precision strategies targeting tumor microenvironments, influenced by trials like TRIBE and PARADIGM. Future efforts should focus on multi-omics integration and innovative delivery systems like circadian-targeted nanoparticles for personalized CRC care.
Keywords: Colorectal cancer1, Antiangiogenesis therapy2, Basic mechanism3, clinical treatment4, Bibliometric analysis5, VOSviewer6, CiteSpace7
Received: 10 Mar 2025; Accepted: 20 Jun 2025.
Copyright: © 2025 Hou, Chen and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jie Chen, Department of Neurology, First Affiliated Hospital of Jiaxing University, Jiaxing, China
Jia-Ming Wu, Department of Gastroenterology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.